Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Aug 24, 2023 7:10am EDT

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

Aug 18, 2023 7:00am EDT

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Jul 17, 2023 7:00am EDT

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

Jul 07, 2023 7:00am EDT

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

Jun 29, 2023 7:00am EDT

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

Jun 13, 2023 7:00am EDT

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Jun 02, 2023 7:00am EDT

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

Jun 01, 2023 7:00am EDT

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

May 30, 2023 7:00am EDT

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

May 15, 2023 7:00am EDT

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

  • arrow_back
  • 1
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding